


8

Topic

Dyslipidemia

Qno 10 Enumerate drug used in Dyslipidemia.



Qno 11 Statins Drug Interaction

Lovastatin	CYP3A4
Simvastatin	
Atorvastatin	CYP2C9 Other pathways including sulfation
Rosuvastatin	
Fluvastatin	
Pravastatin	

9

Q no 12 Give MOA of Statin.

↓ HMG-coA Reductase

↓ Hepatic VLDL Production

↓ Cholesterol

↓ Plasma

Cholesterol.

↑ LDL Receptors

↑ uptake of LDL, and IDL From plasma

↓ LDL

(b) **Clinical uses**

- Atherosclerotic vascular disease
- Acute coronary syndrome
- Reduce LDL Cholesterol level

(c) **Adverse Effect**

- Myopathy
- Hepatic dysfunction
- Teratogen.

(10)

Qno 13 Give **MOA** of Niacin

Decrease VLDL synthesis and LDL
Cholesterol concentrations
Increase HDL cholesterol.

~~Adverse effect~~ **Clinical use**

low HDL cholesterol
Elevated VLDL and LDL

Adverse Effect

- GI irritation
 - Flushing
 - Hepatic toxicity
 - Reduce glucose intolerance
-

Qnoly.

MOA

of Resins

Highly positively charged

Bind negatively charged bile acid

↑ Excretion of bile acid upto 10 folds

↑ hepatic bile acid synthesis from cholesterol.

↓ hepatic cholesterol content

↑ LDL receptor.

↑ uptake of LDL and IDL from plasma.

↓ LDL

Clinical uses

Elevated LDL Cholesterol

Pruritis

Adverse Effect

Constipation

Bloating

Qn015 Drug Therapy for Dyslipidemia.

Statins

Major effect

but also

↓ LDL

↓ TG

Resins

Ezetimibe

Hypercholesterolemia
to decrease LDL

Fibrates

Niacin

Hypertriglyceridemia
to decrease LDL.

Read Table
mini K Pg 295